Neovascular Glaucoma
Conditions
Brief summary
The neovascular glaucoma (NVG) is a refractory type of secondary glaucoma and often lead to frustrated treatment and blindness. It has been confirmed high levels of vascular endothelial growth factor (VEGF) in NVG. Conbercept is an anti-VEGF agent，its role in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic retinopathy has been described. Investigators aim to evaluate the efficacy and safety of intracameral and intravitreal injection of conbercept for the treatment of NVG.
Detailed description
The neovascular glaucoma (NVG) is a refractory type of secondary glaucoma and often lead to frustrated treatment and blindness. It has been confirmed high levels of vascular endothelial growth factor (VEGF) in NVG. Conbercept is an anti-VEGF agent，Its role in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic retinopathy has been described. The intravitreal injection of anti-VEGF agent has shown its therapeutic potential for the early stage of NVG, but not for the late stage. Intracameral injection maybe used as an alternative way for administration. Investigators aim to evaluate the efficacy and safety of intracameral and intravitreal injection of conbercept for the treatment of NVG.
Interventions
PROCEDUREIntracameral injection
Intracameral Conbercept injection for the treatment of NVG
PROCEDUREIntravitreal injection
Intravitreal Conbercept injection for the treatment of NVG
Sponsors
Second Affiliated Hospital of Xi'an Jiaotong University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with a diagnosis of neovascular glaucoma (Stage 1-2-3) * Individuals who are ages 20-80 years old; male or female of chinese * Visual acuity of light perception or better in the study eye * Willing and able to comply with clinic visits and study-related procedures * Provide signed informed consent
Exclusion criteria
* Use of intraocular anti-VEGF agents in the study eye in the past 3 months. * Active ocular or periocular infection in the study eye * Uncontrolled Blood Pressure * Thromboembolism * Congestive Heart Failure * Renal Failure * History of myocardial infarction * History of Stroke * Pregnant or breast-feeding women * Participation in another simultaneous medical investigator or trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| NVI/NVA | 1 week and 1 month after operation | Changes in extent of iris or angle neovascularization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| IOP | 1 week and 1 month after operation | Changes in Intraocular pressure |
| BCVA | 1 week and 1 month after operation | Changes in best corrected visual acuity |
Countries
China
Outcome results
None listed